Matt is a Partner in the Corporate Team. He specialises in public and private mergers and acquisitions, joint ventures, equity capital markets and general corporate advisory work.

His clients include domestic and international corporations, sovereign wealth funds, state-owned enterprises, family offices and financial service providers across a broad range of sectors including health, technology, financial services, insurance, energy and resources, media and telecommunications. His experience includes private acquisitions and disposals, public offerings, schemes of arrangement, minority investments, fund formation and joint ventures in jurisdictions across the world.

Matt worked with leading law firms in Hong Kong and New York before he returned to Sydney in August 2016. He is admitted to practice in NSW, Hong Kong and New York. Matt regularly delivers seminars on a wide range of corporate law related subjects and has also authored a number of publications.

Grant Chamberlain is a Partner of OneVentures, Non-Executive Director of Immutep Ltd, and serves on the Investment Committee of the 1V Venture Credit Fund IV and the OneVentures Growth Fund V. Prior to this, Grant was Australian Head of Mergers & Acquisitions and Financial Sponsors for Bank of America Merrill Lynch.

He has over twenty years’ experience in Australian and cross border mergers and acquisitions, joint ventures and capital markets at global investment banks Bank of America Merrill Lynch, Deutsche Bank and Nomura and has a broad range of experience across industries including technology, healthcare, consumer goods, financial services and natural resources.

Grant has led many of the largest and most complex transactions in Australia in recent years including Woodside’s offer for Oil Search, Iron Mountain’s acquisition of Recall, CSC’s acquisition of UXC, Wilmar and First Pacific’s acquisition of Goodman Fielder, Dai-ichi Life’s acquisition of Tower Australia, Kirin’s acquisition of Lion Nathan, Cephalon’s acquisition of Arana Therapeutics and its investment in Mesoblast, Foster’s acquisition of Southcorp and Webcentral’s merger with Melbourne IT.

He holds an LLB (Hons) and B.Com from the University of Melbourne.

Melanie Farris is an experienced governance and corporate operations professional and non-executive director with 15 years’ experience in listed life sciences companies, as well as extensive experience in the planning, management and delivery of strategic corporate activities including IPO, M&A due diligence and integration.

Currently Chief Governance and Risk Officer and Group Company Secretary for ASX300 company, Telix Pharmaceuticals Limited (ASX:TLX), Melanie’s prior roles include as Non-Executive director and Company Secretary for Factor Therapeutics Limited (ASX: FTT), Non-executive director and Chief Financial Officer for Invion Limited (ASX: IVX), and governance roles at Menzies Research Centre, HRH The Prince of Wales’s Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince’s Foundation.

Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.